Recruitment

Recruitment Status
Completed

Inclusion Criterias

Women at least 4 years postmenopausal
Women at least 4 years postmenopausal

Exclusion Criterias

Medications affecting bone resorption
Medications affecting bone resorption

Summary

Conditions
Osteoporosis, Postmenopausal
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Prevention

Participation Requirements

Age
Younger than 125 years
Gender
Only females

Description

Subjects will participate in four phases of the study: Baseline of 50 days and three intervention phases which include 50 days receiving product followed by 50 days of recovery. The total duration of the study will be 350 days. If participant has not been previously labeled with 41Ca, a 150 day peri...

Subjects will participate in four phases of the study: Baseline of 50 days and three intervention phases which include 50 days receiving product followed by 50 days of recovery. The total duration of the study will be 350 days. If participant has not been previously labeled with 41Ca, a 150 day period is added to the study. Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).

Inclusion Criterias

Women at least 4 years postmenopausal
Women at least 4 years postmenopausal

Exclusion Criterias

Medications affecting bone resorption
Medications affecting bone resorption

Locations

West Lafayette, Indiana, 47907
West Lafayette, Indiana, 47907

Tracking Information

NCT #
NCT01881204
Collaborators
Nestec Ltd.
Investigators
  • Principal Investigator: Connie M Weaver, Ph.D. Purdue University Study Director: Berdine R Martin, PhD Purdue University
  • Connie M Weaver, Ph.D. Purdue University Study Director: Berdine R Martin, PhD Purdue University